Avidity Biosciences Stock Net Asset
| RNA Stock | USD 36.71 0.17 0.46% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Avidity Biosciences' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Avidity Biosciences Company Net Asset Analysis
Avidity Biosciences' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Avidity Biosciences Net Asset | 1.56 B |
Most of Avidity Biosciences' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avidity Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Avidity Biosciences has a Net Asset of 1.56 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Avidity Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avidity Biosciences' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avidity Biosciences could also be used in its relative valuation, which is a method of valuing Avidity Biosciences by comparing valuation metrics of similar companies.Avidity Biosciences is currently under evaluation in net asset category among its peers.
Avidity Fundamentals
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (83.61) % | ||||
| Current Valuation | 3.07 B | ||||
| Shares Outstanding | 120.52 M | ||||
| Shares Owned By Insiders | 5.16 % | ||||
| Shares Owned By Institutions | 94.84 % | ||||
| Number Of Shares Shorted | 16.26 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 3.35 X | ||||
| Price To Sales | 497.90 X | ||||
| Revenue | 10.9 M | ||||
| Gross Profit | (327.32 M) | ||||
| EBITDA | (376.16 M) | ||||
| Net Income | (322.3 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 6.8 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 11.03 X | ||||
| Cash Flow From Operations | (300.87 M) | ||||
| Short Ratio | 9.18 X | ||||
| Earnings Per Share | (3.00) X | ||||
| Target Price | 66.56 | ||||
| Number Of Employees | 391 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 4.44 B | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (893.07 M) | ||||
| Working Capital | 1.44 B | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
| Net Asset | 1.56 B |
About Avidity Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avidity Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avidity Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avidity Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:Check out Avidity Biosciences Piotroski F Score and Avidity Biosciences Altman Z Score analysis. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.